Reuters has hired Bloomberg News reporter Rebecca Spalding to cover mergers and acquisitions in health care, biopharmaceuticals and industrial industries.
She will be based out of New York.
“Thank you all for your kind words in the last few days! It’s a great team and I’m excited for the new challenge,” she wrote on Twitter.
Spalding was based on Boston for Bloomberg. She has written about a drug with a $2 million price tag, a Harvard professor who made $400 million in an biotechnology IPO, Blackstone’s foray into drug development, and how Cambridge, Massachusetts, came to be a magnet for the industry.
She had been at Bloomberg for nearly four years and had previously interned at Forbes.
